Active Recombinant Human TNFRSF10B, Fc Chimera

• Cat.No.: TNFRSF10B-460H
• Product Overview: Recombinant Humantumor necrosis factor receptor superfamily, member 10b was fused to the Fc region of human IgG1 (aa 90-330). The chimeric protein was expressed in modifiedhuman 293 cells.

Specification

• Cat. No.: TNFRSF10B-460H
• Description: TRAILR2, also known as death receptor 5, TNFRSF10B and TNF-related apoptosis-inducing ligand receptor 2, is a type 1 transmembrane protein that contains a death domain in its cytoplasmic domain. TRAILR2 is a receptor for the cytotoxic ligand TRAIL/TNFSF10. TRAILR2 is widely expressed in adult and fetal tissues. TRAILR2 is produced as an ECD-Fc fusion protein with the aim of enhancing its activity. ECD-Fc fusion proteins have an advantage over soluble receptors because many receptors are only functional in dimeric form. Fusion to the Fc domain of IgG1 induces dimerization due to the ability of the Fc domain to form disulfide bonds. The resulting dimeric receptor ECD-Fc mimics the activated form of the receptor and possess enhanced affinity for its cognate ligand relative to its monomeric form.
• Source: human 293 cells.
• Molecular Mass: Under reducing conditions TRAILR1 - Fc Chimera migrates as a broad band between 40 and 50 kDa in SDS-PAGE due to post-translational modifications, in particular glycosylation. This compares with unmodified TRAIL R1 - Fc Chimera that has a predicted monomeric molecular mass of 41.5 kDa.
• PI: TRAILR2 - Fc Chimera separates into a number of isoforms with a pI between 6.0 and 8.0 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified TRAIL R2 - Fc Chimera that has a predicted pI of 6.5.
• % Carbohydrate: TRAILR2 - Fc Chimera consists of 0–25% carbohydrate by weight.
• Glycosylation: TRAILR2 - Fc Chimera contains N- and O-linked oligosaccharides.
• Purity: >95%, as determined by SDS-PAGE and visualized by silver stain.
• Formulation: When reconstituted in 0.5 ml sterile phosphate-buffered saline, the solution will contain 1% human serum albumin (HSA) and 10% trehalose.
• Reconstitution: It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
• Storage: Lyophilized products should be stored at 2 to 8°C. Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C.
• Activity: The ED₅₀of TRAIL R2 - Fc Chimera is typically 38-40 ng/ml as measured by its ability to neutralize TRAIL mediated cytotoxicity using the human leukemic Jurkat cells.

Gene Information

• Gene Name: TNFRSF10B tumor necrosis factor receptor superfamily, member 10b [ Homo sapiens ]
• Synonyms: tumor necrosis factor receptor superfamily, member 10b; DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5; TNFRSF10B; Fas-like protein; death receptor 5; cytotoxic TRAIL receptor-2; apoptosis inducing receptor TRAIL-R2; apoptosis inducing protein TRICK2A/2B; TRAIL receptor 2; TNF-related apoptosis-inducing ligand receptor 2; death domain containing receptor for TRAIL/Apo-2L; tumor necrosis factor receptor-like protein ZTNFR9; p53-regulated DNA damage-inducible cell death receptor(killer); Death receptor 5; OTTHUMP00000123492; CD262 antigen
• Gene ID: 8795
• mRNA Refseq: NM_003842
• Protein Refseq: NP_003833
• MIM: 603612
• UniProt ID: O14763
• Chromosome Location: 8p22-p21
• Pathway: Apoptosis; Cytokine-cytokine receptor interaction; Natural killer cell mediated cytotoxicity; p53 signaling pathway; Apoptosis
• Function: TRAIL binding; caspase activator activity; receptor activity